Yu Jonathan

The PAUL Glaucoma Implant in the management of uveitic glaucoma-3-year follow-up.

To date, this study represents the first publication looking specifically at the efficacy and safety of the PGI in the management of complex uveitic glaucoma.

Preserflo MicroShunt in refractory glaucoma: multicentre european results with up to three years of follow-up.

In a real-world, multicentre setting, the Preserflo MicroShunt showed sustained IOP reduction and decreased medication use over 3 years, supporting its long-term safety and efficacy.

Fields from home: device-independent online perimetry with Melbourne Rapid Fields.

Home-perimetry produced more variable results than in-clinic testing, but the increased testing frequency enabled the potential earlier detection of progression compared to standard in-clinic testing.

Primary Eyecare Glaucoma Service (PEGS): a mixed methods service evaluation.

PEGS is a safe and effective service, reducing the burden for secondary care, while carbon emissions are reduced due to shorter travelling distances, demonstrating environmental sustainability.